Sterile Filtration vs. Terminal Sterilization: Which Sterility Strategy Is Best for Injectable Drugs?

Because the product is sterilized after filling, terminal sterilization offers stronger assurance that contamination cannot occur during manufacturing.

Aseptic processing using sterile filtration requires highly controlled manufacturing environments, including cleanrooms, isolators, or restricted access barrier systems. The process must be carefully validated to prevent microbial contamination during filling operations.

Terminal sterilization simplifies the sterility strategy because the product is sterilized after the container is sealed. However, it requires that the drug formulation and packaging materials withstand sterilization conditions.

Regulatory guidance consistently states that terminal sterilization should be used whenever the product formulation allows. This preference reflects the stronger sterility assurance provided by sterilizing the final product container.

However, for many modern biologics and advanced therapies, sterile filtration followed by aseptic processing is the only viable option.

In those cases, manufacturers must implement robust contamination control strategies, including environmental monitoring, validated filtration processes, and strict aseptic processing controls.

Terminal sterilization is generally preferred when:

• the drug product can tolerate heat or radiation

• small-molecule injectable drugs are being produced

• maximum sterility assurance is required

Sterile filtration is preferred when:

• the drug product is heat-sensitive

• biologics or protein therapeutics are involved

• cell or gene therapy products are being manufactured

Terminal sterilization remains the gold standard for sterility assurance when the drug product can tolerate sterilization conditions.

However, sterile filtration with aseptic processing is essential for many biologics and advanced therapies, where product stability prevents the use of terminal sterilization methods.

The correct strategy ultimately depends on the stability of the drug product and the ability to maintain sterility throughout the manufacturing process.